Thrombotic Microangiopathy After Kidney Transplantation: An Underdiagnosed and Potentially Reversible Entity
Authors:
- Ana ÁvilaAÁAna Ávila
- Eva GavelaEGEva Gavela
- Asunción SanchoASAsunción Sancho
Open Access
- 8 April 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Medicine
- Vol. 8
Abstract
Thrombotic microangiopathy is a rare but serious complication that affects kidney transplant recipients. It appears in 0.8–14% of transplanted patients and negatively affects graft and patient survival. It can appear in a systemic form, with hemolytic microangiopathic anemia, thrombocytopenia, and renal failure, or in a localized form, with progressive renal failure, proteinuria, or arterial hypertension. Post-transplant thrombotic microangiopathy is classified as recurrent atypical hemolytic uremic syndrome orde novothrombotic microangiopathy.De novothrombotic microangiopathy accounts for the majority of cases. Distinguishing between the 2 conditions can be difficult, given there is an overlap between them. Complement overactivation is the cornerstone of all post-transplant thrombotic microangiopathies, and has been demonstrated in the context of organ procurement, ischemia-reperfusion phenomena, immunosuppressive drugs, antibody-mediated rejection, viral infections, and post-transplant relapse of antiphospholipid antibody syndrome. Although treatment of the causative agents is usually the first line of treatment, this approach might not be sufficient. Plasma exchange typically resolves hematologic abnormalities but does not improve renal function. Complement blockade with eculizumab has been shown to be an effective therapy in post-transplant thrombotic microangiopathy, but it is necessary to define which patients can benefit from this therapy and when and how eculizumab should be used.Keywords
This publication has 116 references indexed in Scilit:
- Eculizumab Improves Posttransplant Thrombotic Microangiopathy Due to Antiphospholipid Syndrome Recurrence but Fails to Prevent Chronic Vascular ChangesAmerican Journal of Transplantation, 2013
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2013
- Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical PhenotypeJournal of the American Society of Nephrology, 2013
- Spectrum of Cytomegalovirus-Induced Renal Pathology in Renal Allograft RecipientsTransplantation Proceedings, 2012
- Atypical hemolytic uremic syndromeOrphanet Journal of Rare Diseases, 2011
- De novo Thrombotic Microangiopathy in Renal Allograft Biopsies—Role of Antibody-Mediated RejectionAmerican Journal of Transplantation, 2010
- Expression of Complement Components Differs Between Kidney Allografts from Living and Deceased DonorsJournal of the American Society of Nephrology, 2009
- Recurrent Atypical Hemolytic Uremic Syndrome Associated With Factor I Mutation in a Living Related Renal Transplant RecipientAmerican Journal of Kidney Diseases, 2009
- Transplantation-Related Thrombotic Microangiopathy Triggered by Preemptive Therapy for Hepatitis C Virus InfectionTransplantation, 2008
- VEGF Inhibition and Renal Thrombotic MicroangiopathyNew England Journal of Medicine, 2008